Platinum – Keynote Speaker
The Victorian Government has a proud history of supporting and enhancing cancer research in Victoria. Since 2006 the Victorian Government, through the Victorian Cancer Agency, has invested over $225 million to support translational research infrastructure, workforce initiatives and collaborative projects. High-quality cancer research drives clinical practice improvements and underpins our efforts in prevention, early detection, treatment, wellbeing and support. The Victorian cancer plan outlines the government’s long-term vision to improve cancer outcomes for all Victorians.
The Victorian Cancer Agency is proud to be the Platinum sponsor of GAP2020. We are pleased to be supporting research through the Poster Prizes being offered as part of this conference.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has remained independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Our significant investment of almost 3.5 billion euros in R&D across 2019 drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com.au
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory & Autoimmunity, Cardiovascular & Metabolic Disease and Oncology.
The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit:
Gilead’s mission is to advance patient care by developing therapeutics to treat life threatening diseases. We apply biopharmaceutical science to create medicines to treat conditions in the areas of Haematology/Oncology (ZYDELIG® [idelalisib]), HIV, chronic hepatitis B, chronic hepatitis C and systemic fungal infections (AmBisome® [liposomal amphotericin B]).
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and costsaving generic pharmaceuticals. We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M annually in local clinical trials. Our mission is to discover new ways to improve and extend people’s lives. To find out more about Novartis in Australia visit:
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb , visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
The Victorian Comprehensive Cancer Centre is a powerful alliance of leading research, academic and clinical institutions working together to accelerate and amplify leading-edge cancer research, knowledge and expertise to benefit the Victorian community.
VCCC programs support and enable the alliance members to work strategically and collaboratively together, integrating cancer research, clinical trials and education, to enable and accelerate the translation of scientific evidence into patient and community benefit.
With the support of the Victorian Government, the VCCC seeks to reinforce Victoria’s position at the forefront of research-led, consumer-informed, cancer prevention, detection, treatment and patient care.
EndTobacco is a MD Anderson Cancer Center program that targets the tobacco epidemic with three major goals:
- Reduce smoking in youths
- Reduce the proportion of nonsmokers exposed to secondhand smoke
- Increase counseling and smoking cessation attempts among current smokers